Significance of chromosome 2p gain in ibrutinib-treated chronic lymphocytic leukemia patients

Leukemia. 2021 Nov;35(11):3287-3290. doi: 10.1038/s41375-021-01237-x. Epub 2021 Apr 5.

Authors

Cecelia R Miller¹, Ying Huang², Amy S Ruppert², Jadwiga Labanowska², Samantha M Jaglowski², Kami J Maddocks², Kerry A Rogers², Seema Bhat², Adam S Kittai², Michael Grever², Rosa Lapalombella², Lynne V Abruzzo¹, Nyla A Heerema¹, John C Byrd², Erin K Hertlein^#², Jennifer A Woyach^#³

Affiliations

¹ Department of Pathology, College of Medicine, The Ohio State University, Columbus, OH, USA.
² Division of Hematology, Department of Internal Medicine, College of Medicine, The Ohio State University, Columbus, OH, USA.
³ Division of Hematology, Department of Internal Medicine, College of Medicine, The Ohio State University, Columbus, OH, USA. Jennifer.woyach@osumc.edu.

^# Contributed equally.

No abstract available

Publication types

Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't

MeSH terms

Adenine / analogs & derivatives*
Adenine / therapeutic use
Adult
Aged
Aged, 80 and over
Chromosome Aberrations*
Chromosomes, Human, Pair 2 / genetics*
Cohort Studies
Female
Follow-Up Studies
Gene Dosage*
Humans
Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy
Leukemia, Lymphocytic, Chronic, B-Cell / genetics
Leukemia, Lymphocytic, Chronic, B-Cell / pathology*
Male
Middle Aged
Piperidines / therapeutic use*
Prognosis
Survival Rate

Substances

Piperidines
ibrutinib
Adenine

Grants and funding